Clinical Trials Browser

Phase 3 × NIH × Bortezomib × Clear all

NCT02112916 2025-12-01

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Phase 3 Active not recruiting

847 enrolled 19 charts

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01371981 2025-11-26

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3 Active not recruiting

1,645 enrolled 32 charts

Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Phase 3 Completed

11 enrolled 6 charts

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01109004 2021-12-09

BMT CTN 0702

Phase 3 Completed

758 enrolled 21 charts

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT00522392 2015-06-26

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Phase 3 Terminated

48 enrolled 9 charts

Multiple Myeloma